AzizNazhaMD

PubMed

• Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
  Abdulrahman Alhajahjeh, Aziz Nazha> ;Current Hematologic Malignancy Reports. 2024 Feb 1
• 4 citations
  Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
  Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
• 1 citations
  Thirty-Day Unplanned Hospital Readmissions in Patients With Cancer and the Impact of Social Determinants of Health: A Machine Learning Approach.
  Nickolas Stabellini, Aziz Nazha, Nikita Agrawal, Merilys Huhn, John Shanahan, Nelson Hamerschlak, Kristin Waite, Jill S Barnholtz-Sloan, Alberto J Montero> ;JCO Clinical Cancer Informatics. 2023 Jul 1
• How I read an article that uses machine learning methods.
  Aziz Nazha, Olivier Elemento, Shannon McWeeney, Moses Miles, Torsten Haferlach> ;Blood Advances. 2023 Aug 22
• 1 citations
  Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study.
  Tao Zhang, Paul Auer, Jing Dong, Corey Cutler, Amy E Dezern, Shahinaz M Gadalla, H Joachim Deeg, Aziz Nazha, Karen-Sue Carlson, Stephen Spellman, Yung-Tsi Bolon, Wael ...> ;Journal of Hematology & Oncology. 2023 Apr 11
• 4 citations
  Patient-specific comorbidities as prognostic variables for survival in myelofibrosis.
  Sochacki, A., Bejan, C., Zhao, S., Patel, A., Kishtagari, A., Spaulding, T., Silver, A., Stockton, S., Pugh, K., Dorand, R., Bhatta, M., Strayer, N., Zhang, S., Snider...> ;Blood Advances. 2023 Mar 14
• Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.
  Jing Dong, Christopher Staffi Buradagunta, Tao Zhang, Stephen Spellman, Yung-Tsi Bolon, Amy E DeZern, Shahinaz M Gadalla, H Joachim Deeg, Aziz Nazha, Corey Cutler, Cha...> ;Journal of Hematology & Oncology. 2023 Mar 10
• 1 citations
  Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
  Mrinal M Patnaik, Amer M Zeidan, Eric Padron, Uwe Platzbecker, David A Sallman, Amy E DeZern, Rafael Bejar, Mikkael Sekeres, Justin Taylor, Richard F Little, Jan P Bew...> ;Leukemia. 2022 Dec 1
• 13 citations
  Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
  Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A Sekeres, David P Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M ...> ;Leukemia. 2022 Dec 1
• 5 citations
  A machine learning model of response to hypomethylating agents in myelodysplastic syndromes.
  Nathan Radakovich, David A Sallman, Rena Buckstein, Andrew Brunner, Amy Dezern, Sudipto Mukerjee, Rami Komrokji, Najla Al-Ali, Jacob Shreve, Yazan Rouphail, Anne Parme...> ;Iscience. 2022 Oct 21
• 4 citations
  An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.
  Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F Sanz, David A Sallman, Vale...> ;Blood Advances. 2023 Jun 27
• 5 citations
  The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
  Tamara K Moyo, Jason H Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C Seegmiller, Aaron T Gerds, Gregory D Ayers, Amy E Dezern, Aziz Nazha, Peter Va...> ;BMC Cancer. 2022 Sep 24
• 1 citations
  Personalized model to predict seizures based on dynamic and static continuous EEG monitoring data.
  Moein Amin, Christopher Newey, Vineet Punia, Stephen Hantus, Aziz Nazha> ;Epilepsy & Behavior. 2022 Oct 1
• 8 citations
  Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis.
  Marie Robin, Liesbeth C de Wreede, Eric Padron, Katerina Bakunina, Pierre Fenaux, Linda Koster, Aziz Nazha, Dietrich W Beelen, Raajit K Rampal, Katja Sockel, Rami S Ko...> ;Blood. 2022 Sep 22
• 2 citations
  Why Machine Learning Should Be Taught in Medical Schools.
  Matthew Nagy, Nathan Radakovich, Aziz Nazha> ;Medical Science Educator. 2022 Apr 1
• 3 citations
  Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow...
  Hemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B Alkhateeb, Susan Bal, Mohamed A Kharfan-Dabaja, Bhagirathbhai Dholaria, Francine Foss, Lohith Gowda, Deepa...> ;Transplantation and Cellular Therapy. 2022 Apr 1
• 30 citations
  Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors...
  Guru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Sherif M Badawy, Amer Beitinjaneh, Chr...> ;JAMA Oncology. 2022 Mar 1
• Can the computer see what the human sees
  Aziz Nazha> ;Blood. 2021 Nov 18
• 3 citations
  A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
  Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen W.L. Yee, Andrew Dalovisio, Eunice S. Wang, Jua...> ;Blood Cancer Journal. 2021 Oct 30
• 2 citations
  Simplified Pediatric Index of Mortality 3 Score by Explainable Machine Learning Algorithm.
  Orkun Baloglu, Matthew Nagy, Chidiebere Ezetendu, Samir Q. Latifi, Aziz Nazha> ;Critical Care Explorations. 2021 Oct 19
• 8 citations
  A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.
  Nathan Radakovich, Manja Meggendorfer, Luca Malcovati, C. Beau Hilton, Mikkael A. Sekeres, Jacob Shreve, Yazan Rouphail, Wencke Walter, Stephan Hutter, Anna Gallì, Sar...> ;Blood Advances. 2021 Nov 9
• 35 citations
  Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
  Aziz Nazha, Rami S. Komrokji, Manja Meggendorfer, Xuefei Jia, Nathan Radakovich, Jacob Shreve, C. Beau Hilton, Yasunubo Nagata, Betty K. Hamilton, Sudipto Mukherjee, N...> ;Journal of Clinical Oncology. 2021 Aug 18
• 4 citations
  What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)
  Rami S. Komrokji, Najla Al Ali, Eric Padron, Jeffrey E. Lancet, Aziz Nazha, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Guillermo Garcia-Manero, Mikkael A. Sekere...> ;Leukemia & Lymphoma. 2021 Jun 11
• 4 citations
  Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
  Wei Wang, Paul L. Auer, Tao Zhang, Stephen R. Spellman, Karen-Sue B. Carlson, Aziz Nazha, Yung-Tsi Bolon, Wael Saber> ;Transplantation and Cellular Therapy. 2021 May 13
• 5 citations
  Personalized Prediction of Hospital Mortality in COVID-19 positive patients.
  Daniel Rozenbaum, Jacob Shreve, Nathan Radakovich, Abhijit Douggal, Lara Jehi, Aziz Nazha> ;Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 2021 May 12
• Join now to see all

Journal Articles

• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies  
  Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick..., Blood Cancer J, 1/31/2015
• Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical and Therapeutic Implications  
  Nazha A, Khoury JD, Rampal R, Daver N, Oncologist, 1/24/2015
• Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?  
  Nazha A, Sekeres MA, Gore SD, Zeidan AM, Oncologist, 1/20/2015
• Genomic Patterns Associated with Hypoplastic Compared to Hyperplastic Myelodysplastic Syndromes  
  Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, Maciejewski JP, Haematologica, 1/13/2015
• The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes  
  Nazha A, Seastone DJ, Keng M, Hobson S, Kalaycio M, Maciejewski JP, Sekeres MA, Leukemia Lymphoma, 1/1/2015
• Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia  
  Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J, Clin Lymphoma Myeloma Leuk, 1/24/2014
• Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis  
  Nazha A, Jorgensen JL, Verstovsek S, Leuk Lymphoma, 1/24/2014
• Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics  
  Nazha A, Kantarjian HM, Bhatt VR, et al, Clin Lymphoma Myeloma Leuk, 1/21/2014
• Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid ...  
  Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonzalez GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K..., Clin Lymphoma Myeloma Leuk, 1/15/2014
• Pharmacotherapy of polycythemia vera  
  Tam CS, Nazha A, Verstovsek S, Expert Opinion on Orphan Drugs Dec, 12/1/2013
•  
  Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju..., Am J Hematol, 11/1/2013
• Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months  
  Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J, Haematologica, 11/1/2013
• Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis  
  Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S, Leuk Lymphoma, 11/1/2013
• Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse  
  Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F, Leuk Lymphoma, 10/9/2013
• The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia  
  Nazha A, Romo CG, Kantarjian H, Cortes J, Haematologica, 10/1/2013
• Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia  
  Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A, Expert Opin Pharmacother, 10/1/2013
• The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia  
  Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F, Front Oncol, 9/1/2013
• Acute myeloid leukemia in the elderly: do we know who should be treated and how?  
  Nazha A, Ravandi F, Leuk Lymphoma, 8/28/2013
• Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia  
  Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J, Clin Lymphoma Myeloma Leuk, 8/19/2013
• Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy  
  Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A, Clin Lymphoma Myeloma Leuk, 8/1/2013
• Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities  
  Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J, Blood, 6/1/2013
• Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options  
  Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F, Clin Lymphoma Myeloma Leuk, 2/1/2013
• Pharmacotherapy of polycythemia vera  
  Tam CS, Nazha A, Verstovsek S, Expert Opinion on Orphan Drugs, 1/1/2013
• Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities  
  Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J, Blood, 1/1/2013
• Join now to see all

Abstracts/Posters

• FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate PotentialClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor ExpansionClinically Relevant Abstract
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Aziz Nazha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). 
  Houston, TX - 1/1/2015
• Somatic Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). 
  Washington, DC - 1/1/2015
• A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML). 
  Houston, TX - 1/1/2014
• A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). 
  San Francisco, CA - 1/1/2014
• Clofarabine, Idarubicin, and Cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia 
  San Diego, CA (2011); Atlanta, GA (2012) - 12/1/2012
• Clofarabine, Idarubicin, and Cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia. 
  Atlanta, GA - 1/1/2012
• Join now to see all